Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18528944 | 1.00 | NFE2L2 (0.46) | NFE2L2TRPA1ALDH1A1CYP1A2MAOA | |
| SCHEMBL6057243 | 0.90 | ALDH1A1 (0.50) | NFE2L2TRPA1ALDH1A1CYP1A2MAOA | |
| SCHEMBL6057240 | 0.90 | ALDH1A1 (0.50) | NFE2L2TRPA1ALDH1A1CYP1A2MAOA | |
| SCHEMBL28420132 | 0.86 | ALDH1A1 (0.42) | NFE2L2TRPA1ALDH1A1CYP1A2MAOA | |
| SCHEMBL11022950 | 0.81 | NFE2L2 (0.46) | NFE2L2TRPA1ALDH1A1CYP1A2MAOA | |
| SCHEMBL11022955 | 0.81 | NFE2L2 (0.46) | NFE2L2TRPA1ALDH1A1CYP1A2MAOA | |
| SCHEMBL14690155 | 0.78 | NFE2L2 (0.54) | NFE2L2TRPA1MAOASIGMAR1MAOB | |
| SCHEMBL14690157 | 0.78 | NFE2L2 (0.54) | NFE2L2TRPA1MAOASIGMAR1MAOB | |
| SCHEMBL14690153 | 0.78 | NFE2L2 (0.54) | NFE2L2TRPA1MAOASIGMAR1MAOB | |
| SCHEMBL28619294 | 0.76 | CDK4 (0.47) | TRPA1ALDH1A1CYP1A2MAOAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980765-B2 | Isothiocyanatostilbenes as a novel method and product for treating cancer | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) | 2021-04-20 | — | — | US | claimed |
| US-20190000791-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | Board of Supervisors for the University of Louisiana System | 2019-01-03 | — | — | US | claimed |
| WO-2017031036-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | GRAY ALANA LEA (US) | 2017-02-23 | — | — | WO | claimed |
| US-10980765-B2 | Isothiocyanatostilbenes as a novel method and product for treating cancer | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980765-B2 | Isothiocyanatostilbenes as a novel method and product for treating cancer | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980765-B2 | Isothiocyanatostilbenes as a novel method and product for treating cancer | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190000791-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | Board of Supervisors for the University of Louisiana System | 2019-01-03 | — | — | US | disclosed |
| US-20190000791-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | Board of Supervisors for the University of Louisiana System | 2019-01-03 | — | — | US | disclosed |
| WO-2017031036-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | GRAY ALANA LEA (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031036-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | GRAY ALANA LEA (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20100029613-A1 | TREATMENT AND PREVENTION OF EPILEPSY | UNIVERSITY OF ROCHESTER (US) | 2010-02-04 | — | — | US | disclosed |
| EP-1426762-A1 | REMEDIES FOR HEART DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980765-B2 | Isothiocyanatostilbenes as a novel method and product for treating cancer | SI, PCMT1, HDAC8 | NFE2L2 2965/4885TRPA1 813/4885ALDH1A1 819/4885 |
| US-20190000791-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | SI, PCMT1, HDAC8 | NFE2L2 2965/4885TRPA1 813/4885ALDH1A1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.